Table 4. Review of various retrospective cohorts and important clinical trials.
| Study | No. of O examined | No. of AO examined | No. of non-1p/19q codeleted O identified | No. of non-1p/19q codeleted AO identified | Method used |
|---|---|---|---|---|---|
| Ducray F and Sanson M et al. 2008 [25] | 22 | 24 | 9 (40.9%) | 12 (50%) | array-CGH |
| Durand KS and Labrousse FJ et al. 2010 [30] | 2 | 5 | 0 | 0 | LOH |
| Labussiere M and Sanson M et al. 2010 [27] | 90 | 119 | 43 (47.8%) | 55 (46.2%) | array-CGH |
| Buckley PG and Farrell MA et al. 2011 [33] | 15 | 12 | 3 (20%) | 3 (25%) | FISH and array-CGH |
| Ducray F and Sanson M et al. 2011 [35] | 73 | 133 | 30 (51%) | 42 (45%) | array-CGH |
| Eigenbrod S and Kretzschmar HA et al. 2011 [37] | 10 | 10 | 1 (10%) | 4 (40%) | LOH |
| Goze C and Duffau H et al. 2012 [29] | 21 | - | 6 (29%) | - | LOH |
| Jiao Y and Yan H et al. 2012 [36] | 21 | 29 | 8 (38.1%) | 3 (10.3%) | LOH |
| Li S and Jiang T et al. 2012 [14] | - | 36 | - | 22 (61.1%) | DHPLC |
| Sahm F and Hartmann C et al. 2012 [34] | 9 | 9 | 2 (22.2%) | 1 (11.1%) | LOH and MLPA |
| Arita H and Ichimura K et al. 2013 [10] | 34 | 31 | 7 (23%) | 7 (27%) | MLPA |
| Cairncross G and Mehta M et al. 2013 [1] | - | 150 | - | 43 (29%) | FISH |
| Frenel JS and Campone M et al. 2013 [32] | 0 | 43 | 0 | 17 (42.5%) | FISH |
| Jiang H and Lin S et al. 2013 [28] | - | 24 | - | 7 (29.2%) | FISH |
| Mur P and Melendez B et al. 2013 [31] | 19 | 14 | 14 (42.4%) | FISH | |
| van den Bent MJ and Hoang-Xuan K et al.2013 [5] | - | 316 (AO and AOA) | - | 236 (75%, AO and AOA) | FISH |
| Chan AK and Ng HK et al.2014 [15] | 19 | 11 | 7 (36.8%) | 4 (36.4%) | FISH |
| Gillet E and Idbaih A et al. 2014 [23] | 32 | - | 16 (50%) | - | LOH |
| Sahm F and von Deimling A et al. 2014 [11] | 43 (OA) | 11 (25.6%, OA) | FISH | ||
| Brat DJ and Zhang J et al. 2015 [51] | 65 | 44 | 27 (41.5%) | 13 (29.5%) | Genomic Analysis |
| Chan AK and Ng HK et al.2015 [6] | 18 | 3 | 7 (41.2%) | 1 (33.3%) | FISH |
| Gleize V and Sanson M et al. 2015 [24] | 60 | 43 | 4 (6.7%) | 9 (20.9%) | LOH |
| Weller M and Reifenberger G et al. 2015 [26] | 3 | 3 | 0 | 1 (33.3%) | array-CGH |
| Dubbink HJ and van den Bent MJ et al. 2016 [22] | - | 93 | - | 40 (47.1%) | LOH, FISH and NGS |
O, oligodendroglioma; AO, anaplastic oligodendroglioma; OA, Oligoastrocytoma; FISH, fluorescence in situ hybridization; LOH, loss of heterozygosity; MLPA, multiplex ligation-dependent probe amplification; DHPLC, denaturing high-performance liquid chromatography; NGS, next-generation sequencing; array-CGH, array-based comparative genomic hybridization